The biopharmaceutical company Biopharma plans to launch a plant in Arad, Romania, in late 2027, with an initial investment of EUR85 million, company president Kostyantyn Yefimenko told the Interfax-Ukraine news agency.
“We have already completed construction of the building and will finish installing all utility lines by September 1. We have already ordered the filling line. By the end of June, we will have contracted for the reactor equipment and all other process equipment. We will begin operations in December 2027,” Yefimenko said.
The initial investment in the plant in Arad is EUR85 million; the Romanian project as a whole will consist of four phases of varying sizes. Total investment in the plants in Uzhhorod and Arad is approximately $500 million.
He noted that the company’s development is not focused on a single project.
“Bila Tserkva is our flagship plant. We’re not shifting our focus; we’re developing all of them—Uzhhorod and Arad—and we’ll continue to build in Latin America,” Yefimenko said.
As previously reported, Biopharma plans to launch the first phase of its plant for the production of pharmaceutical products and immunobiological preparations in Uzhhorod in September 2026, which will provide a full cycle of blood plasma processing. The company has already invested EUR67 million in construction; the total cost of the first phase is EUR75 million. According to the plan, the volume of blood plasma-derived drug production in Uzhhorod will be twice that of production in Bila Tserkva, amounting to up to 1.5 million liters of blood plasma per year; the project in Romania is twice as large.
During the “Industrial Evolution: Manufacturing Drives the Economy” forum in Bila Tserkva, Yefimenko also announced that Biopharma had registered its albumin product in Brazil.
Biopharma exports its products to dozens of countries and plans to expand its presence in Europe, the Middle East, and Latin America while continuing to increase its production capacity.
